Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial

Autor: Mohammad Hossein Fallah Mehrabadi, Monireh Hajimoradi, Ali Es-haghi, Saeed Kalantari, Mojtaba Noofeli, Ali Rezaei Mokarram, Seyed Hossein Razzaz, Maryam Taghdiri, Ladan Mokhberalsafa, Fariba Sadeghi, Vahideh Mohseni, Safdar Masoumi, Rezvan Golmoradi-Zadeh, Mohammad Hasan Rabiee, Masoud Solaymani-Dodaran, Seyed Reza Banihashemi

Publikováno v: Vaccines, Vol 12, Iss 11, p 1255 (2024)

Protective antibodies in the upper respiratory tract prevent the spread of COVID-19 in the community. Intranasal vaccines could raise the specific secretory IgA and IgG levels. This is a single-center, randomized, double-blind, placebo-controlled cli

Externí odkaz: https://doaj.org/article/9bdd8c8a8e4a454996ec4e6423c87718

Non-antibiotic prevention and treatment against Acinetobacter baumannii infection: Are vaccines and adjuvants effective strategies?

Autor: Yue Hu, Xianqin Zhang, Shanshan Deng, Changwu Yue, Xu Jia, Yuhong Lyu

Publikováno v: Frontiers in Microbiology, Vol 14 (2023)

Acinetobacter baumannii (A. baumannii) is a Gram-negative opportunistic pathogen widely attached to the surface of medical instruments, making it one of the most common pathogens of nosocomial infection, and often leading to cross-infection and co-in

Externí odkaz: https://doaj.org/article/2cd64d38c22643dd9f5f5e238e722be5

Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants

Autor: Xuesong Xu, Yi Hong, Erjing Chen, Yaping Wang, Biao Ma, Jiali Li, Wei Su, Yuxin Zhou, Mingzhou Zhang

Publikováno v: Vaccines, Vol 10, Iss 12, p 2110 (2022)

Safe and effective vaccines for Corona Virus Disease 2019 (COVID-19) can prevent the virus from infecting human populations and treat patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this study, we discuss the i

Externí odkaz: https://doaj.org/article/67d1a4b9ba8d4a2aa172b1fe258e43b6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge

Autor: Ram Nechooshtan, Sharon Ehrlich, Marika Vitikainen, Arik Makovitzki, Eyal Dor, Hadar Marcus, Idan Hefetz, Shani Pitel, Marilyn Wiebe, Anne Huuskonen, Lilach Cherry, Edith Lupu, Yehuda Sapir, Tzvi Holtzman, Moshe Aftalion, David Gur, Hadas Tamir, Yfat Yahalom-Ronen, Yuval Ramot, Noam Kronfeld, David Zarling, Anne Vallerga, Ronen Tchelet, Abraham Nyska, Markku Saloheimo, Mark Emalfarb, Yakir Ophir

Publikováno v: Nechooshtan, R, Ehrlich, S, Vitikainen, M, Makovitzki, A, Dor, E, Marcus, H, Hefetz, I, Pitel, S, Wiebe, M, Huuskonen, A, Cherry, L, Lupu, E, Sapir, Y, Holtzman, T, Aftalion, M, Gur, D, Tamir, H, Yahalom-Ronen, Y, Ramot, Y, Kronfeld, N, Zarling, D, Vallerga, A, Tchelet, R, Nyska, A, Saloheimo, M, Emalfarb, M & Ophir, Y 2022, ' Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel ® 85 Protects K18-hACE2 Mice against Lethal Virus Challenge ', Vaccines, vol. 10, no. 12, 2119 . https://doi.org/10.3390/vaccines10122119
Vaccines; Volume 10; Issue 12; Pages: 2119

SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield, commercia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18e033dee1cdd46f411ff7f3bcc150a
https://doi.org/10.3390/vaccines10122119